Company intelligence / Profile preview

MeiliLing Biotech

Guangzhou, Guangdong, China

Ownership: Private
Development stage: Other

Overview

MeiliLing Biotech is an emerging biotechnology company focused on the discovery and development of novel small molecule therapeutics for the treatment of cancer and metabolic disorders. The company leverages its proprietary drug discovery engine to identify high-value targets and optimize lead compounds with improved pharmacological profiles. Currently in the pre-clinical stage, MeiliLing Biotech is advancing a pipeline of internal programs aimed at addressing significant unmet medical needs. The firm is headquartered in China and is actively seeking strategic partnerships to accelerate its research and development efforts.

Therapeutic areas: OncologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on MeiliLing Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MeiliLing Biotech.

Explore the full profile